Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Steven Jay Isakoff, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Steven Isakoff and Nadine Tung.
Connection Strength

1.073
  1. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Res Treat. 2021 Oct; 189(3):641-651.
    View in: PubMed
    Score: 0.239
  2. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020 05 10; 38(14):1539-1548.
    View in: PubMed
    Score: 0.215
  3. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol. 2018 11 01; 36(31):3134-3143.
    View in: PubMed
    Score: 0.195
  4. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18.
    View in: PubMed
    Score: 0.062
  5. A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Res Treat. 2021 Sep; 189(2):411-423.
    View in: PubMed
    Score: 0.059
  6. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.
    View in: PubMed
    Score: 0.059
  7. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385.
    View in: PubMed
    Score: 0.059
  8. Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clin Cancer Res. 2020 06 01; 26(11):2704-2710.
    View in: PubMed
    Score: 0.053
  9. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016 08 01; 22(15):3764-73.
    View in: PubMed
    Score: 0.041
  10. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014 Aug; 25(8):1656-63.
    View in: PubMed
    Score: 0.036
  11. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4224-6.
    View in: PubMed
    Score: 0.030
  12. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. J Clin Oncol. 2009 May 20; 27(15_suppl):551.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.